Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

3.26USD
19 Dec 2014
Price Change (% chg)

$-0.01 (-0.31%)
Prev Close
$3.27
Open
$3.26
Day's High
$3.32
Day's Low
$3.20
Volume
3,701,265
Avg. Vol
1,153,941
52-wk High
$5.58
52-wk Low
$1.31

GERN.OQ

Chart for GERN.OQ

About

Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication.... (more)

Overall

Beta: 2.16
Market Cap (Mil.): $512.51
Shares Outstanding (Mil.): 157.21
Dividend: --
Yield (%): --

Financials

  GERN.OQ Industry Sector
P/E (TTM): -- 179.07 38.47
EPS (TTM): -0.25 -- --
ROI: -36.18 -0.72 18.25
ROE: -36.18 -1.88 19.13
Search Stocks

US STOCKS-Wall St flat after retail sales, UMich data

* Indexes: Dow off 0.01 pct, S&P up 0.05 pct, Nasdaq up 0.07 pct (Adds UMich data, Virgin America IPO)

14 Nov 2014

US STOCKS-Wall St opens flat after retail sales, UMich data on tap

* Indexes: Dow off 0.04 pct, S&P flat, Nasdaq off 0.11 pct (Updates to market open)

14 Nov 2014

US STOCKS-Wall St to open flat after retail sales, UMich data due

* Futures up: Dow 7 pts, S&P 0.5 pt, Nasdaq 0.75 pt (Adds data, updates prices)

14 Nov 2014

US STOCKS-Futures flat ahead of retail sales, UMich data

* Futures up: Dow 11 pts, S&P 1.5 pt, Nasdaq 2.75 pts (Adds premarket actives)

14 Nov 2014

US STOCKS-Futures little changed ahead of data

NEW YORK, Nov 14 - U.S. stock index futures were little changed on Friday, with the S&P on track for a fourth straight weekly advance, ahead of data on consumer sentiment.

14 Nov 2014

Geron sells last drug in pipeline to J&J unit

- Geron Corp licensed its cancer compound, the last in its pipeline, to a unit of Johnson & Johnson for up to $935 million, sending its shares up as much as 33 percent in extended trading.

13 Nov 2014

Geron sells last drug in pipeline to J&J unit

Nov 13 - Geron Corp licensed its cancer compound, the last in its pipeline, to a unit of Johnson & Johnson for up to $935 million, sending its shares up as much as 33 percent in extended trading.

13 Nov 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks